As is known, aging itself is an inflammatory process. From this perspective, do you think non-steroidal anti-inflammatory drugs can contribute to longevity? I leave an article link below:
Can we assert this? Even the article starts with:
Most age-related diseases and aging itself are associated with chronic inflammation.
This paper doesnât start by equating inflammation with aging.
This makes me wonder about where to focus.
Things that start going wrong can certainly manifest|produce inflammation and inflammation has follow on consequences we should address.
Lotâs of things help and the paper touches on some. This site has seen discussion of things lite Attiaâs and Searâs recommendations of :
- EPA | DHA fish oil &
- Aspirin
Searâs makes the case for their synergistic effects.
Even poor sleep can trigger inflammation.
My point or maybe my questions:
- Does inflammation arise or get triggered as a symptom of something else that goes awry?
- Should we focus on the thing(s) that trigger the inflammation (where possible) rather than just the inflammation?
Maybe we need to do both.
1 Like
Naproxen came as one of the 14 of 400 âprescription medsâ negatively associated with mortality in the trawl of the UK Biobank data.
I take it on my rest days. Little downside.
3 Likes
Good questions⌠Iâve heard many geoscientists talk about âinflammagingâ, it seems to one of the defining aspects of aging:
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Most older individuals develop inflammageing, a condition characterized by elevated levels of blood inflammatory markers that carries high susceptibility to chronic morbidity, disability, frailty, and premature death. Potential mechanisms of inflammageing include genetic susceptibility, central obesity, increased gut permeability, changes to microbiota composition, cellular senescence, NLRP3 inflammasome activation, oxidative stress caused by dysfunctional mitochondria, immune cell dysregulation, and chronic infections. Inflammageing is a risk factor for cardiovascular diseases (CVDs), and clinical trials suggest that this association is causal. Inflammageing is also a risk factor for chronic kidney disease, diabetes mellitus, cancer, depression, dementia, and sarcopenia, but whether modulating inflammation beneficially affects the clinical course of non-CVD health problems is controversial. This uncertainty is an important issue to address because older patients with CVD are often affected by multimorbidity and frailty â which affect clinical manifestations, prognosis, and response to treatment â and are associated with inflammation by mechanisms similar to those in CVD. The hypothesis that inflammation affects CVD, multimorbidity, and frailty by inhibiting growth factors, increasing catabolism, and interfering with homeostatic signalling is supported by mechanistic studies but requires confirmation in humans. Whether early modulation of inflammageing prevents or delays the onset of cardiovascular frailty should be tested in clinical trials.
2 Likes
Yes, daily and long-term use of nonsteroidal anti-inflammatory drugs may negatively affect life expectancy due to adverse side effects. But could using them intermittently, such as once a week or once every two weeks, be beneficial in reducing inflammation? For example, the calcification in the joints of patients with osteoarthritis decreases after using nonsteroidal anti-inflammatory drugs. This is a well-known scientific finding.